Bli medlem
Bli medlem

Du är här


ObsEva SA: ObsEva Announces Plans to Conduct Initial Public Offering in the United States

ObsEva SA / ObsEva Announces Plans to Conduct Initial Public Offering in the
United States. Processed and transmitted by Nasdaq Corporate Solutions. The
issuer is solely responsible for the content of this announcement.
GENEVA, SWITZERLAND, 17 October, 2016 - ObsEva SA, a Swiss biopharmaceutical
company focused on the development and commercialization of novel
therapeutics for serious conditions that compromise a woman's reproductive
health and pregnancy, today announced that the Company plans to conduct an
initial public offering in the United States.

This announcement is being made pursuant to and in accordance with Rule 135
under the Securities Act of 1933, as amended. As required by Rule 135, this
press release does not constitute an offer to sell or the solicitation of an
offer to buy securities, and shall not constitute an offer, solicitation or
sale in any jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of
that jurisdiction.

The timing and the terms of this initial public offering have not yet been

Media Contact:

Liz Bryan
Spectrum Science

202-955-6222 x2526

Company Contact:

Delphine Renaud
ObsEva, CEO Office

+41 22 552 1550

Press Release


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ObsEva SA via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.